CNS Pharmaceuticals, Inc. (CNSP) stock
CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.56−0.35 (-9.07%)
Close on Nov 20, 2026Market cap $5.20MP/E –Yield –
CNS Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
CNS Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2024 was -$17.12M. For fiscal 2025 it was -$13.83M. The highest annual figure on record is -$716.39K in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.83M | – |
| FY2024 | Dec 31, 2024 | -$17.12M | – |
| FY2023 | Dec 31, 2023 | -$14.14M | – |
| FY2022 | Dec 31, 2022 | -$10.56M | – |
| FY2021 | Dec 31, 2021 | -$13.54M | – |
| FY2020 | Dec 31, 2020 | -$7.34M | – |
| FY2019 | Dec 31, 2019 | -$3.57M | – |
| FY2018 | Dec 31, 2018 | -$716.39K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.65M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.34M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.24M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.54M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.38M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.08M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.24M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.00M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.31M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.27M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.75M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.49M | – |
| Q3 FY2019 | Sep 30, 2019 | -$378.32K | – |
| Q2 FY2019 | Jun 30, 2019 | -$625.26K | – |
| Q1 FY2019 | Mar 31, 2019 | -$82.69K | – |
| Q4 FY2018 | Dec 31, 2018 | -$159.49K | – |
See a number that looks wrong?